Shocking Truth: Why 70% of Americans Are Ignoring Life-Saving Pneumococcal Vaccines! Are You Next?

Boosting pneumococcal vaccine coverage among people living with HIV (PLWH) is crucial, according to a recent study published in Vaccine: X. This research highlights the need for targeted patient strategies and improved coordination across healthcare levels to enhance vaccine adherence in this vulnerable population. By addressing both individual patient needs and broader health-system factors, the study suggests that better collaboration between primary care and specialized healthcare can significantly increase immunization rates.

Vaccination is especially vital for individuals with HIV, as this virus compromises the immune system. The Minority HIV/AIDS Fund states, “Vaccines are especially important for people with chronic health conditions like HIV, which can make it harder to fight off vaccine-preventable diseases like pneumococcal disease or the flu.” Those with HIV are at higher risk for severe complications from infections, making vaccinations an integral part of their healthcare regimen.

However, a separate study in Vaccines points out that global vaccination guidelines for PLWH are inconsistent, often leading to varied recommendations for different patients diagnosed with HIV. This inconsistency emphasizes the need for more research and targeted efforts to improve vaccination coverage among this high-risk group, particularly in the context of pneumococcal disease.

Pneumococcal Disease Risk Among PLWH

The risks associated with pneumococcal diseases are alarmingly high for PLWH. Research from aidsmap indicates that severe cases of pneumococcal disease are up to 50 times more prevalent in adults living with HIV. Even those on HIV medication still face a seven-fold increase in risk. Given these statistics, it's critical for healthcare providers to educate PLWH about the importance of adhering to their pneumococcal vaccination schedules.

The study aimed to gain insights into pneumococcal vaccine coverage among this population. The authors noted, “Globally, there is little research on adults with HIV infection regarding vaccine coverage, adherence, and factors that influence it.” To fill this gap, they set out to determine vaccination coverage and identify the clinical and social characteristics associated with the administration of the pneumococcal vaccine among PLWH in Andalusia, Spain, who received their first dose between January 1, 2014, and March 31, 2022.

Pneumococcal Vaccine Coverage in PLWH

The researchers conducted a retrospective cohort study involving 4,938 adults living with HIV who were vaccinated against pneumococcal bacteria within the Andalusian Public Health System. They analyzed the time interval between patients' first and second doses of the vaccine, considering cases “censored” if patients were lost to follow-up after their first dose. Key variables included age, sex, hospital follow-up destination, and the clinical stage of illness.

The results were concerning: only 37.2% of participants received their second dose within the first year following their initial vaccination. By the end of the study period, coverage increased to 80%, but this still fell short of the recommended 95% threshold. The authors emphasized that “people living with HIV are at higher risk of bacterial pneumonia and invasive pneumococcal disease,” with associated increases in morbidity and mortality compared to the general population. The findings underscore the urgent need for improved vaccination strategies for PLWH, particularly in Spain, where overall vaccination rates remain low.

Researchers advocate for a targeted approach to enhance vaccination coverage among this population. They suggest leveraging the expertise of healthcare providers at all levels, including pharmacists and infectious disease specialists. Despite the valuable insights these professionals offer, the study indicates that primary care involvement is crucial for boosting immunization rates among PLWH.

In summary, the findings highlight a significant gap in pneumococcal vaccine coverage for people living with HIV, calling for urgent attention and coordinated efforts to strengthen immunization practices. The study serves as a reminder that PLWH face unique health challenges, and consistent vaccination is a critical aspect of comprehensive care.

References:
1. Heredia-Ruiz MR, Jiménez-Murillo JL, Lopez-Gigosos R, et al. Pneumococcal vaccine coverage and factors linked to second-dose administration in HIV patients in Andalusia (Spain), 2014–2022. Vaccine X. 2025;28:100769-100769. https://doi.org/10.1016/j.jvacx.2025.100769
2. Vaccines and people with HIV. Minority HIV/AIDS Fund. December 12, 2025. Accessed December 19, 2025. https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/immunizations-recommended-for-people-living-with-hiv
3. About HIV. CDC. January 14, 2025. Accessed December 19, 2025. https://www.cdc.gov/hiv/about/index.html
4. De Vito A, Colpani A, Trunfio M, et al. Living with HIV and getting vaccinated: a narrative review. Vaccines. 2023;11(5):896. https://doi.org/10.3390/vaccines11050896
5. Stanford A. Pneumococcal disease and HIV. August 2023. Accessed December 19, 2025. https://www.aidsmap.com/about-hiv/pneumococcal-disease-and-hiv